• Japanese
  • Korean
  • Chinese
Cover Image

Naturlose (Type 2 Diabetes) - Analysis and Forecasts to 2020

Abstract

Naturlose (Type 2 Diabetes) - Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, "Naturlose (Type 2 Diabetes) - Analysis and Forecasts to 2020" provides Naturlose sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Naturlose
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Naturlose including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2012-2020 for Naturlose in each of the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drug's performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

TOC

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Introduction 5

  • 2.1 Diabetes Market 5
  • 2.2 Epidemiology 5
    • 2.2.1 Prevalence 5
    • 2.2.2 Mortality 7
  • 2.3 Etiology and Risk Factors 9
    • 2.3.1 Obesity 9
    • 2.3.2 Sedentary Lifestyle 9
    • 2.3.3 Family History and Genetics 9
    • 2.3.4 Ethinicity 9
    • 2.3.5 Old Age 9
  • 2.4 Economic Impact of Diabetes 9
  • 2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

  • 3.1 Type 2 Diabetes Market 12
  • 3.2 Type 2 Diabetes Market Forecasts and CAGR 13
  • 3.3 Type 2 Diabetes Market: Drivers and Restraints 14
    • 3.3.1 Drivers 14
    • 3.3.2 Restraints 15

4 Classification of Diabetes 16

  • 4.1 Types of Diabetes 16
    • 4.1.1 Type1 Diabetes 16
    • 4.1.2 Type 2 Diabetes 16
    • 4.1.3 Gestational Diabetes 16
  • 4.2 Diabetes Complications 16
    • 4.2.1 Cardiovascular Disease 16
    • 4.2.2 Nephropathy 17
    • 4.2.3 Neuropathy 17
    • 4.2.4 Amputation 17
    • 4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

  • 6.1 Insulin 19
  • 6.2 Oral Medications 19
    • 6.2.1 Sulfonylureas (SUR) 19
    • 6.2.2 Biguanides (BGDs) 20
    • 6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
    • 6.2.4 Meglitinides 21
    • 6.2.5 Thiazolidinediones (TZDs) 22
    • 6.2.6 Dipeptidyl Peptidase IV (DPP-4) Inhibitors 23
    • 6.2.7 Oral Combination Therapy 23
  • 6.3 Other Injectionable Medications 24
    • 6.3.1 Pramlintide 24
    • 6.3.2 Exenatide 24
  • 6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Naturlose 25

  • 7.1 Introduction 25
  • 7.2 Mechanism of Action 25
  • 7.3 Clinical Studies 25
  • 7.4 Factors Affecting Sales of Naturlose 25
    • 7.4.1 Almost No Calories 25
    • 7.4.2 High Safety Profile 26
  • 7.5 Drug Evaluation 26
    • 7.5.1 Drug Risk Benefit Score 26
    • 7.5.2 Intensity of Competition 27
  • 7.6 Sales Forecasts 27
    • 7.6.1 Target Patient Pool 27
    • 7.6.2 Dosing 27
    • 7.6.3 Market Penetration 27
    • 7.6.4 Annual Cost of Therapy 28
    • 7.6.5 Sales Projections of Naturlose 28

8 Diabetes Market: Appendix 37

  • 8.1 Market Definitions 37
  • 8.2 List of Abberiviations 37
  • 8.3 Research Methodology 37
    • 8.3.1 Coverage 38
    • 8.3.2 Secondary Research 38
    • 8.3.3 Forecasting 38
    • 8.3.4 Number of patients approved to take the drug 38
    • 8.3.5 Net Penetration of Drug 39
    • 8.3.6 Net Annual Dosing 39
    • 8.3.7 Annual Cost of Therapy 39
  • 8.4 Drug Sales Estimates Model 39
  • 8.5 Contact Us 39
  • 8.6 Disclaimer 40
  • 8.7 Sources 40

List of Tables

1.1 List of Tables

  • Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
  • Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
  • Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
  • Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
  • Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
  • Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
  • Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
  • Table 8: Diabetes Drugs Evolution 18
  • Table 9: Phase II Trial Results 25
  • Table 10: Drug Risk Benefit Score of Naturlose 26
  • Table 11: Naturlose, Type 2 Diabetes, Global, Sales Estimates ($m), 2012-2020 29
  • Table 12: Naturlose, Type 2 Diabetes, The US, Sales Estimates ($m), 2012-2020 29
  • Table 13: Naturlose, Type 2 Diabetes, UK, Sales Estimates ($m), 2012-2020 30
  • Table 14: Naturlose, Type 2 Diabetes, France, Sales Estimates ($m), 2012-2020 31
  • Table 15: Naturlose, Type 2 Diabetes, Germany, Sales Estimates ($m), 2012-2020 32
  • Table 16: Naturlose, Type 2 Diabetes, Italy, Sales Estimates ($m), 2012-2020 33
  • Table 17: Naturlose, Type 2 Diabetes, Spain, Sales Estimates ($m), 2012-2020 34
  • Table 18: Naturlose, Type 2 Diabetes, Japan, Sales Estimates ($m), 2012-2020 35

List of Figures

1.2 List of Figures

  • Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010 6
  • Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030 6
  • Figure 3: Diabetes, World, Mortality, 2010 7
  • Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
  • Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010-2020 13
  • Figure 6: Mechanism of Action of Sulfonylurea 19
  • Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
  • Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
  • Figure 9: Mechanism of Action of Thiazolidinediones 22
  • Figure 10: Mechanism of Action of DPP-IV Inhibitors 23
  • Figure 11: Type 2 Diabetes, Global, Market Share as per Classes (%), 2010 24
  • Figure 12: Naturlose, Type 2 Diabetes , Global, Sales Estimates ($m), 2012-2020 28
  • Figure 13: Naturlose, Type 2 Diabetes, The US, Sales Estimates ($m), 2012-2020 29
  • Figure 14: Naturlose, Type 2 Diabetes, UK Sales Estimates ($m), 2012-2020 30
  • Figure 15: Naturlose, Type 2 Diabetes, France, Sales Estimates ($m), 2012-2020 31
  • Figure 16: Naturlose, Type 2 Diabetes, Germany, Sales Estimates ($m), 2012-2020 32
  • Figure 17: Naturlose, Type 2 Diabetes, Italy, Sales Estimates ($m), 2012-2020 33
  • Figure 18: Naturlose, Type 2 Diabetes, Spain, Sales Estimates ($m), 2012-2020 34
  • Figure 19: Naturlose, Type 2 Diabetes, Japan, Sales Estimates ($m), 2012-2020 35
  • Figure 20: Naturlose, Type 2 Diabetes, Sales Distribution by Country (%), 2020 36
  • Figure 21: Patients Approved for the Drug 39
Show More
Pricing